DUBLIN – The Heptares unit of Sosei Group Corp. is spinning out two drug development programs for narcolepsy into two standalone companies, Orexia Ltd. and Inexia Ltd., which have received aggregate funding commitments of up to €40 million (US$45.8 million) from the London-based venture capital fund Medicxi.